Bagsværd, Denmark, 14 June 2017 - Novo Nordisk today announced the submission of a Type II Variation application to the European Medicines Agency (EMA) for including data in the label for Tresiba® (insulin degludec) from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba® compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes.
|Katrine Sperling||+45 4442 6718||[email protected]|
|Ken Inchausti (US)||+1 609 786 8316||[email protected]|
|Peter Hugreffe Ankersen||+45 3075 9085||[email protected]|
|Hanna Ögren||+45 3079 8519||[email protected]|
|Anders Mikkelsen||+45 3079 4461||[email protected]|
|Kasper Veje (US)||+1 609 235 8567||[email protected]|
Company announcement No 44/2017
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire